Utah Medical Products (FRA:UTM) Beneish M-Score: -2.67 (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UTM Utah Medical Products Inc FRA:UTM
73 GF Score
Price €58.50
GF Value €49.20
! 8 Warning Signs
View Full Analysis

What is Utah Medical Products Beneish M-Score?

Utah Medical Products FRA:UTM -2.50% 73 Beneish M-Score is -2.67 as of Aug. 27, 2026. GuruFocus rates FRA:UTM with a GF Score™ of 73/100 and a GF Value™ of €49.20. The stock has 8 warning signs investors should review. Among 772 Medical Devices & Instruments companies, Utah Medical Products ranks better than 59.84% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.67 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Utah Medical Products's Beneish M-Score or its related term are showing as below:

FRA:UTM' s Beneish M-Score Range Over the Past 10 Years
Min: -3.21   Med: -2.76   Max: -2.04
Current: -2.67

During the past 13 years, the highest Beneish M-Score of Utah Medical Products was -2.04. The lowest was -3.21. And the median was -2.76.


Utah Medical Products Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Utah Medical Products's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Utah Medical Products Beneish M-Score Chart

Utah Medical Products Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.60 -2.86 -3.13 -2.22 -2.78

Utah Medical Products Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.44 -2.65 -2.78 -2.74 -2.67

FRA:UTM vs EMBC, SMTI, PDEX: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Utah Medical Products's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Utah Medical Products Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Utah Medical Products's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Utah Medical Products's Beneish M-Score falls into.


FRA:UTM
73GF Score
Utah Medical Products Inc FRA:UTM
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Utah Medical Products Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Utah Medical Products for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.12+0.528 * 0.9904+0.404 * 0.8577+0.892 * 0.8773+0.115 * 1.1526
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.181+4.679 * -0.027874-0.327 * 0.8751
=-2.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Total Receivables was €3.09 Mil.
Revenue was 7.403 + 7.545 + 7.724 + 8.36 = €31.03 Mil.
Gross Profit was 4.13 + 4.569 + 4.495 + 4.775 = €17.97 Mil.
Total Current Assets was €87.36 Mil.
Total Assets was €108.13 Mil.
Property, Plant and Equipment(Net PPE) was €8.36 Mil.
Depreciation, Depletion and Amortization(DDA) was €2.11 Mil.
Selling, General, & Admin. Expense(SGA) was €7.77 Mil.
Total Current Liabilities was €1.80 Mil.
Long-Term Debt & Capital Lease Obligation was €0.17 Mil.
Net Income was 2.331 + 2.252 + 2.191 + 2.242 = €9.02 Mil.
Non Operating Income was 0.553 + 0.152 + 0.568 + 0.595 = €1.87 Mil.
Cash Flow from Operations was 1.2 + 2.689 + 2.969 + 3.304 = €10.16 Mil.
Total Receivables was €3.15 Mil.
Revenue was 8.629 + 8.982 + 8.746 + 9.015 = €35.37 Mil.
Gross Profit was 4.851 + 5.123 + 5.083 + 5.228 = €20.29 Mil.
Total Current Assets was €81.82 Mil.
Total Assets was €104.74 Mil.
Property, Plant and Equipment(Net PPE) was €8.89 Mil.
Depreciation, Depletion and Amortization(DDA) was €2.69 Mil.
Selling, General, & Admin. Expense(SGA) was €7.50 Mil.
Total Current Liabilities was €1.95 Mil.
Long-Term Debt & Capital Lease Obligation was €0.22 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3.094 / 31.032) / (3.149 / 35.372)
=0.099704 / 0.089025
=1.12

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(20.285 / 35.372) / (17.969 / 31.032)
=0.573476 / 0.579047
=0.9904

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (87.355 + 8.36) / 108.128) / (1 - (81.823 + 8.893) / 104.735)
=0.114799 / 0.133852
=0.8577

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=31.032 / 35.372
=0.8773

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.688 / (2.688 + 8.893)) / (2.108 / (2.108 + 8.36))
=0.232104 / 0.201376
=1.1526

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(7.774 / 31.032) / (7.503 / 35.372)
=0.250516 / 0.212117
=1.181

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.169 + 1.797) / 108.128) / ((0.222 + 1.954) / 104.735)
=0.018182 / 0.020776
=0.8751

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(9.016 - 1.868 - 10.162) / 108.128
=-0.027874

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Utah Medical Products has a M-score of -2.64 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.67 mean?
Utah Medical Products (FRA:UTM) has a Beneish M-Score of -2.67 as of Aug. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Utah Medical Products and its competitors. According to the industry distribution chart, Utah Medical Products ranks #310 out of 772 companies in the Medical Devices & Instruments industry, placing it in the top 40.2%.
Is Utah Medical Products' Beneish M-Score too high?
Utah Medical Products' current Beneish M-Score is -2.67. Based on the distribution chart, Utah Medical Products ranks #310 out of 772 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Utah Medical Products has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Utah Medical Products' Beneish M-Score compare to EMBC and SMTI?
According to the Medical Devices & Instruments industry distribution chart, Utah Medical Products ranks #310 out of 772 companies for Beneish M-Score. This puts Utah Medical Products in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Utah Medical Products and its competitors. Utah Medical Products's current Beneish M-Score is -2.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Utah Medical Products stock overvalued right now?
Utah Medical Products (FRA:UTM) has a current Beneish M-Score of -2.67. The stock's GF Value™ is €49.20, compared to a current price of €58.50 — trading 18.9% above its estimated fair value. The current Beneish M-Score is -2.67. Utah Medical Products' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Utah Medical Products (FRA:UTM), the current Beneish M-Score is -2.67 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Utah Medical Products (FRA:UTM) Overvalued in 2026?

Based on GuruFocus' analysis, Utah Medical Products stock appears to be overvalued. The current stock price of €58.50 is trading 18.9% above its estimated GF Value™ of €49.20.

Key valuation signals for FRA:UTM:

  • Beneish M-Score: -2.67
  • GF Value™: €49.20 vs. price of €58.50 (18.9% above fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the FRA:UTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Utah Medical Products Business Description

Other Exchanges UTMD:USA
Address 7043 South 300 West, Midvale, UT, USA, 84047
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
73GF Score

Get the complete analysis for FRA:UTM

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.50
Price
€49.20
GF Value